找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: New Trends in Diagnosis and Management of Stroke; Klaus Poeck,Erich Bernd Ringelstein,Werner Hacke Book 1987Latest edition Springer-Verlag

[复制链接]
楼主: Menthol
发表于 2025-3-25 05:30:58 | 显示全部楼层
发表于 2025-3-25 08:36:27 | 显示全部楼层
Platelet Inhibitors and the Prevention of Stroked the progression of the atherosclerotic lesions of the vessel wall. A great variety of laboratory tests have shown enhanced platelet function in patients with vascular disease, e.g., enhanced platelet aggregation, formation of “in vivo aggregates,” shortening of platelet life span, and liberation o
发表于 2025-3-25 14:56:59 | 显示全部楼层
发表于 2025-3-25 17:33:08 | 显示全部楼层
Risk and Benefit of Anticoagulation in Patients with Acute Hemispheric Infarctions: Preliminary Resuo have had cardiogenic brain embolism experience reinfarction within a 2-week period after the initial attack [4–6, 14] (Table 1). This rate is similar to that for most cardiac sources of emboli (Table 2) except for nonvalvular atrial fibrillation, which seems to be characterized by a lower risk of
发表于 2025-3-25 21:26:57 | 显示全部楼层
发表于 2025-3-26 02:26:40 | 显示全部楼层
发表于 2025-3-26 04:30:05 | 显示全部楼层
Effect of Nimodipine on the Cerebral Circulation and Acute Ischemic Strokes the “final common pathway”, resulting in catabolism and cell necrosis due to calcium overload. Treatment with calcium entry blockers, therefore, may be a new approach to arresting, and possibly preventing, destruction of cerebral tissue in stroke patients. The calcium entry blocker nimodipine was
发表于 2025-3-26 09:06:42 | 显示全部楼层
发表于 2025-3-26 15:12:56 | 显示全部楼层
Effect of Nimodipine on the Cerebral Circulation and Acute Ischemic Strokemulticenter study was conducted. The data from this study strongly suggest that patients with acute ischemic stroke benefit from treatment with 120 mg nimodipine, started with 24 h after onset, combined with a “Standard” treatment, e. g., hemodilution by low molecular weight dextran. The conclusion
发表于 2025-3-26 19:06:59 | 显示全部楼层
invaluable to both researchers and clinicians studying the development of and treating patients with Alzheimer’s Disease.978-1-4939-6034-7978-1-62703-598-9Series ISSN 2197-7224 Series E-ISSN 2197-7232
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-20 18:05
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表